Macquarie Group becomes substantial shareholder in Clinical Labs

Macquarie Group Limited and its controlled entities became a substantial holder in Australian Clinical Labs Limited (ASX:ACL) on September 29, 2025. They acquired a 5.11% voting power, representing 9,995,276 ordinary shares. This stake is held through various Macquarie entities including Macquarie Bank Limited and Macquarie Investment Management Australia Limited, with interests arising from stock borrowing, trustee capacities, and investment management.

Concurrently, State Street Australia Ltd ACF Australian Ethical Investment Limited reported a change in its substantial holding in Australian Clinical Labs Limited on September 30, 2025. Their voting power decreased from 7.58% (14,877,241 votes) to 6.49% (12,704,151 votes). This reduction resulted from on-market sales of FPO securities between August 26, 2025, and September 30, 2025, totaling 2,136,023 shares for AUD 5,148,827.68.